A Correction on
TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report
By Sultan AW, Grießhammer E, Hinrichs C, Trenkmann L, Oschlies I, Hanitsch LG, Haibel H, Schneider T and Leistner R (2026) Front. Immunol. 16:1729525. doi: 10.3389/fimmu.2025.1729525
There was a mistake in Table 2 as published. An incorrect file was erroneously published in place of Table 2. The corrected Table 2 appears below.
Table 2. Comparison of diagnostic results in idiopathic multicentric Castleman disease with TAFRO features (iMCD-TAFRO), hemophagocytic lymphohistiocytosis (HLH), and other relevant mimics (such as iMCD-NOS, autoimmune diseases, and lymphoma) (3, 7–9, 14, 17).
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: case report, combined IL-6 and IL-1 inhibition, idiopathic multicentric Castleman disease, iMCD, TAFRO syndrome
Citation: Frontiers Production Office (2026) Correction: TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report. Front. Immunol. 17:1786154. doi: 10.3389/fimmu.2026.1786154
Received: 12 January 2026; Accepted: 12 January 2026;
Published: 23 January 2026.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2026 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, cHJvZHVjdGlvbi5vZmZpY2VAZnJvbnRpZXJzaW4ub3Jn